Send us Feedback

Elan Corporation (ELN)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

ELN » Topics » Our share price is volatile, which could result in substantial losses for investors purchasing shares.

This excerpt taken from the ELN 6-K filed Mar 30, 2009.
Our share price is volatile, which could result in substantial losses for investors purchasing shares.
 
The market prices for our shares and for securities of other companies engaged primarily in biotechnology and pharmaceutical development, manufacture and distribution are highly volatile. The market price of our shares likely will continue to fluctuate due to a variety of factors, including:
 
•  Material public announcements by us;
 
•  Developments regarding Tysabri;
 
•  Developments regarding any strategic alternatives;
 
•  Results of clinical trials with respect to our products under development (in particular bapineuzumab) and those of our competitors;
 
•  The timing of new product launches by others and us;
 
•  Events related to our marketed products and those of our competitors;
 
•  Regulatory issues affecting us;
 
•  Availability and level of third-party reimbursement;
 
•  Developments relating to patents and other intellectual property rights;
 
•  Political developments and proposed legislation affecting the pharmaceutical industry;
 
•  Economic and other external factors;
 
•  Hedge or arbitrage activities by holders of our securities;
 
•  Period-to-period fluctuations in our financial results or results that do not meet or exceed market expectations; and
 
•  Market trends relating to or affecting share prices across our industry, whether or not related to results or news regarding our competitors or us.
 
This excerpt taken from the ELN 6-K filed Mar 30, 2007.
Our share price is volatile, which could result in substantial losses for investors purchasing shares.
 
The market prices for our shares and for securities of other companies engaged primarily in biotechnology and pharmaceutical development, manufacture and distribution are highly volatile. The market price of our shares likely will continue to fluctuate due to a variety of factors, including:
 
•  Material public announcements by us;
 
•  Developments regarding Tysabri;
 
•  The timing of new product launches by others and us;
 
•  Events related to our marketed products and those of our competitors;
 
•  Regulatory issues affecting us;
 
•  Availability and level of third-party reimbursement;
 
•  Developments relating to patents and other intellectual property rights;
 
•  Results of clinical trials with respect to our products under development and those of our competitors;
 
•  Political developments and proposed legislation affecting the pharmaceutical industry;
 
•  Economic and other external factors;
 
•  Hedge or arbitrage activities by holders of our securities;
 
•  Period-to-period fluctuations in our financial results or results that do not meet or exceed market expectations; and
 
•  Market trends relating to or affecting share prices across our industry, whether or not related to results or news regarding our competitors or us.
 
This excerpt taken from the ELN 6-K filed Mar 31, 2006.
Our share price is volatile, which could result in substantial losses for investors purchasing shares.
The market prices for our shares and for securities of other companies engaged primarily in biotechnology and pharmaceutical development, manufacture and distribution are highly volatile. For example, on 28 February 2005, we lost approximately 70% of our market capitalisation and on 31 March 2005, we lost more than 50% of our market capitalisation. The market price of our shares likely will continue to fluctuate due to a variety of factors, including:
• Material public announcements by us;
 
• Developments regarding Tysabri;
 
• The timing of new product launches by others and us;
 
• Events related to our marketed products and those of our competitors;
 
• Regulatory issues affecting us;
 
• Availability and level of third-party reimbursement;
 
• Developments relating to patents and other intellectual property rights;
 
• Results of clinical trials with respect to our products under development and those of our competitors;
 
• Political developments and proposed legislation affecting the pharmaceutical industry;
 
• Economic and other external factors;
 
• Hedge or arbitrage activities by holders of our securities;
 
• Period-to-period fluctuations in our financial results or results that do not meet or exceed market expectations; and
 
• Market trends relating to or affecting share prices across our industry, whether or not related to results or news regarding our competitors or us.
Elan Corporation, plc 2005 Annual Report  167

Table of Contents

This excerpt taken from the ELN 6-K filed Apr 11, 2005.

Our share price is volatile, which could result in substantial losses for investors purchasing shares.

The market prices for our shares and for securities of other companies engaged primarily in biotechnology and pharmaceutical development, manufacture and distribution are highly volatile. For example, on 28 February 2005, we lost approximately 70% of our market capitalisation and on 31 March 2005, we lost more than 50% of our market capitalisation. The market price of our shares likely will continue to fluctuate due to a variety of factors, including:

 

•

Material public announcements by us;

 

•

Developments regarding Tysabri;

 

•

The timing of new product launches by others and us;

 

•

Events related tour marketed products and those of our competitors;

 

•

Regulatory issues affecting us;

 

•

Availability and level of third party reimbursement;

 

•

Developments relating tpatents and other intellectual property rights;

 

•

Results of clinical trials with respect tour products under development and those of our competitors;

 

•

Political developments and proposed legislation affecting the pharmaceutical industry;

 

•

Economic and other external factors;

 

•

Hedge or arbitrage activities by holders of our securities;

 

•

Period-to-period fluctuations in our financial results or results that dnot meet or exceed market expectations; and

 

•

Market trends relating tor affecting share prices across our industry, whether or not related tresults or news regarding our competitors or us.

EXCERPTS ON THIS PAGE:

6-K
Mar 30, 2009
6-K
Mar 30, 2007
6-K
Mar 31, 2006
6-K
Apr 11, 2005

RELATED TOPICS for ELN:

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki